- Diagnostics
- 1 min read
DGHS: Can use plasma therapy in moderate cases
Convalescent plasma therapy is allowed as an investigational therapy for use in Covid-19 patients. The clinical management protocol prescribed by the government recommends convalescent plasma by plasmapheresis as in Covid-19 patients with a few safeguards.
Convalescent plasma therapy is allowed as an investigational therapy for use in Covid-19 patients. The clinical management protocol prescribed by the government recommends convalescent plasma by plasmapheresis as in Covid-19 patients with a few safeguards.
According to the DGHS, under the Central Drugs Standard Control Organisation, the special prerequisites while considering convalescent plasma include ABO compatibility and cross-matching of the donor plasma. Recipient should also be closely monitored for several hours post transfusion for any transfusion-related adverse events. “Use should be avoided in patients with IgA deficiency or immunoglobulin allergy,” it said. The recommended dose for the therapy is variable ranging from 4 to 13 ml/kg (usually 200 ml single dose given slowly over not less than 2 hours).
The health ministry had recently revised blood transfusion guidelines to include collection of convalescent plasma under the clinical trials protocol from people who have recovered from Covid-19 infection. The Indian Red Cross Society (IRCS) is also working to create a database of potential convalescent plasma donors for hospitals treating Covid-19 patients.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions